Bio News
Novo Nordisk has selected Omnicom as its U.S. media advertising agency in a deal worth 739.4 billion won ($520 million). Under the agreement, Novo Nordisk will end its partnership with WPP’s Wavemaker, which began in 2020. Through the new partnership, Novo Nordisk plans to increase consumer awareness of treatments for chronic diseases, including obesity and diabetes.
Biobook Team
biobookmedia@biobook.co.krParagon Spin-Off Velaris Goes Public Through Reverse Merger With Alaunos
Syndax halts development of Niktimvo for pulmonary fibrosis; shares plunge 17%
BioNTech’s mRNA Cancer Vaccine Misses Primary Endpoint for Progression-Free Survival in Phase 3 Trial
Roche Signs $1.6 Billion Deal With China’s Rona for ALK7 Obesity Drug
Formycon and Zydus’ Keytruda Biosimilar Is First to Be Accepted for FDA Review
Pfizer Signs $500 Million Protein Degrader Deal With Enodia
